Product NDC: | 67767-142 |
Proprietary Name: | Bupropion Hydrochloride |
Non Proprietary Name: | Bupropion Hydrochloride |
Active Ingredient(s): | 300 mg/1 & nbsp; Bupropion Hydrochloride |
Administration Route(s): | ORAL |
Dosage Form(s): | TABLET, EXTENDED RELEASE |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 67767-142 |
Labeler Name: | Actavis South Atlantic LLC |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | ANDA077285 |
Marketing Category: | ANDA |
Start Marketing Date: | 20100331 |
Package NDC: | 67767-142-05 |
Package Description: | 500 TABLET, EXTENDED RELEASE in 1 BOTTLE (67767-142-05) |
NDC Code | 67767-142-05 |
Proprietary Name | Bupropion Hydrochloride |
Package Description | 500 TABLET, EXTENDED RELEASE in 1 BOTTLE (67767-142-05) |
Product NDC | 67767-142 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | Bupropion Hydrochloride |
Dosage Form Name | TABLET, EXTENDED RELEASE |
Route Name | ORAL |
Start Marketing Date | 20100331 |
Marketing Category Name | ANDA |
Labeler Name | Actavis South Atlantic LLC |
Substance Name | BUPROPION HYDROCHLORIDE |
Strength Number | 300 |
Strength Unit | mg/1 |
Pharmaceutical Classes | Aminoketone [EPC],Dopamine Uptake Inhibitors [MoA],Increased Dopamine Activity [PE],Increased Norepinephrine Activity [PE],Norepinephrine Uptake Inhibitors [MoA] |